Literature DB >> 1372614

Phospholipid binding of antiphospholipid antibodies and placental anticoagulant protein.

L R Sammaritano1, A E Gharavi, C Soberano, R A Levy, M D Lockshin.   

Abstract

We evaluated the interaction of antiphospholipid antibodies (aPL) with placental anticoagulant protein I (PAP I), a calcium-dependent phospholipid binding protein which may act as a natural anticoagulant. Clotting assays showed additive prolongation of clotting times with aPL and PAP I. ELISA and vesicle phospholipid binding studies showed PAP I inhibition of aPL binding to phospholipid but no inhibition of PAP I-phospholipid binding by aPL. aPL and PAP I interact additively in anticoagulant activity in in vitro clotting systems and compete for phospholipid in ELISA system. These data support the hypotheses that aPL and PAP I may recognize similar phospholipid epitopes and that in vivo interaction may occur.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1372614     DOI： 10.1007/bf00918270

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN： 0271-9142            Impact factor:   8.317


  60 in total

1.  Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.

Authors:  M Galli; P Comfurius; C Maassen; H C Hemker; M H de Baets; P J van Breda-Vriesman; T Barbui; R F Zwaal; E M Bevers
Journal:  Lancet       Date:  1990-06-30       Impact factor: 79.321

2.  Correlation between lupus anticoagulants and anticardiolipin antibodies in patients with prolonged activated partial thromboplastin times.

Authors:  B M Alving; C F Barr; D B Tang
Journal:  Am J Med       Date:  1990-02       Impact factor: 4.965

3.  Simultaneous lupus anticoagulant and anticardiolipin assays and clinical detection of antiphospholipids.

Authors:  M H Rosove; P M Brewer; A Runge; K Hirji
Journal:  Am J Hematol       Date:  1989-10       Impact factor: 10.047

4.  Common domain structure of Ca2+ and lipid-binding proteins.

Authors:  M J Geisow
Journal:  FEBS Lett       Date:  1986-07-14       Impact factor: 4.124

5.  Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant.

Authors:  F De Wolf; L O Carreras; P Moerman; J Vermylen; A Van Assche; M Renaer
Journal:  Am J Obstet Gynecol       Date:  1982-04-01       Impact factor: 8.661

6.  Primary antiphospholipid syndrome: features of patients with raised anticardiolipin antibodies and no other disorder.

Authors:  C G Mackworth-Young; S Loizou; M J Walport
Journal:  Ann Rheum Dis       Date:  1989-05       Impact factor: 19.103

7.  Anticoagulant properties of placenta protein 4 (annexin V).

Authors:  J Römisch; U Schorlemmer; K Fickenscher; E P Pâques; N Heimburger
Journal:  Thromb Res       Date:  1990-12-01       Impact factor: 3.944

8.  Relationship between anti-cardiolipin and anti-endothelial cell antibodies in systemic lupus erythematosus.

Authors:  A Vismara; P L Meroni; A Tincani; E N Harris; W Barcellini; A Brucato; M Khamashta; G R Hughes; C Zanussi; G Balestrieri
Journal:  Clin Exp Immunol       Date:  1988-11       Impact factor: 4.330

9.  A sensitive test demonstrating lupus anticoagulant and its behavioural patterns.

Authors:  T Exner; K A Rickard; H Kronenberg
Journal:  Br J Haematol       Date:  1978-09       Impact factor: 6.998

10.  Phospholipid binding properties of human placental anticoagulant protein-I, a member of the lipocortin family.

Authors:  J F Tait; D Gibson; K Fujikawa
Journal:  J Biol Chem       Date:  1989-05-15       Impact factor: 5.157
View more
  11 in total

Review 1.  Antigenic specificities of "antiphospholipid" autoantibodies.

Authors:  R A Roubey
Journal:  Springer Semin Immunopathol       Date:  1994

Review 2.  Physiopathology of thrombosis induced by antiphospholipid antibodies.

Authors:  J M Zini
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

3.  Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression.

Authors:  Xiao-Xuan Wu; Seth Guller; Jacob H Rand
Journal:  Am J Obstet Gynecol       Date:  2011-06-24       Impact factor: 8.661

Review 4.  Antiphospholipid antibodies and the antiphospholipid syndrome.

Authors:  E N Harris; S S Pierangeli
Journal:  Springer Semin Immunopathol       Date:  1994

5.  Preventing antiphospholipid antibody-induced fetal loss: a new idea.

Authors:  M D Lockshin
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

6.  Activation of cultured vascular endothelial cells by antiphospholipid antibodies.

Authors:  R Simantov; J M LaSala; S K Lo; A E Gharavi; L R Sammaritano; J E Salmon; R L Silverstein
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

7.  Prevalence of anticardiolipin antibodies in pregnancies with history of repeated miscarriages.

Authors:  Ligia Cosentino Junqueira Franco Spegiorin; Eloísa A Galão; Lúcia Buchalla Bagarelli; Antonio Hélio Oliani; José Maria Pereira de Godoy
Journal:  Open Rheumatol J       Date:  2010-08-26

8.  Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers.

Authors:  Jacob H Rand; Xiao-Xuan Wu; Anthony S Quinn; Pojen P Chen; James J Hathcock; Douglas J Taatjes
Journal:  Blood       Date:  2008-06-24       Impact factor: 22.113

Review 9.  Autoimmunity and recurrent pregnancy losses.

Authors:  Ricard Cervera; Juan Balasch
Journal:  Clin Rev Allergy Immunol       Date:  2010-12       Impact factor: 8.667

10.  Inhibitor(s) of natural anti-cardiolipin autoantibodies.

Authors:  Z Kra-Oz; M Lorber; Y Shoenfeld; Y Scharff
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.